The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,504.00
Bid: 12,502.00
Ask: 12,506.00
Change: 100.00 (0.81%)
Spread: 4.00 (0.032%)
Open: 12,500.00
High: 12,562.00
Low: 12,444.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Semis, energy outperform in a bleak market

Mon, 04th Jan 2021 17:29

* US equity indexes decline around 2%
* Real estate weakest S&P sector; energy falls least
* STOXX 600 ends up ~0.7%
* Dollar up, crude down; spot gold jumps, US 10-Year yield
~0.91%

Jan 4 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com


SEMIS, ENERGY OUTPERFORM IN A BLEAK MARKET (1206 EST/1706
GMT)
While U.S. stocks are a sea of red on Monday, the
semiconductor sector was the only gainer for much of the
morning. That said, even chips have lost their lustre, though
they are still among the best performers on a relative basis in
a dreary market.
The energy sector is also holding up better than
much of the market after in early afternoon trade.
One reason chips were doing better than most on Monday
morning may be uncertainty about the future, according to Kim
Forrest, chief investment officer at Bokeh Capital Partners in
Pittsburgh:
"It’s the easy thesis: We don’t know what the future holds,
with respect to what technology will be a winner this year, but
we know there is demand for more computers and connection from
the analog to the digital world."
These uncertainties about the future, including Tuesday's
Georgia Senate run-off election as well as restrictions that
could come from rising covid cases, cast a pall over the broader
market.
And after rising as much as 2.7% earlier in the session,
confidence even in semis waned sharply and the Philadelphia
Semiconductor index was last down 0.5%. Even Micron
Technology, couldn't resist the general flow and was last
down ~1% even after its positive news in the form of price
traget increases from UBS to $90 from $82 and from Morgan
Stanley to $88 from $80.
In comparison Wall Street's three major indexes are all down
around 2%, and while the broad S&P technology sector
is down 2.3%. Gold is up 2% gain.
Here is you mid-session snapshot:



(Sinéad Carew)
*****

IN WITH THE NEW: 2021 STARTS WITH STRONG PMI, CONSTRUCTION
DATA (1105 EST/1605 GMT)
Two indicators released on Monday helped investors ease
their way into the new year with welcome signs of economic
recovery from the pandemic recession, now entering its 12th
month.
The National Bureau of Economic Research determined the
United States economy entered recession in February 2020.
Activity in the U.S. manufacturing sector grew in December
at a faster pace than previously reported, according to global
financial information firm IHS Markit.
Markit's final purchasing managers index (PMI)
hit a reading last month of 57.1, finishing a tumultuous year at
a six-year high.
The data marks an increase from the 56.5 rate originally
reported. A PMI number above 50 indicates activity in the sector
expanded from the prior month.
"Producers of machinery and equipment reported sustained
strong demand, suggesting companies are increasing their
investment spending," writes Chris Williamson, chief business
economist at Markit.
The news, however, is not all rainbows and lollipops.
"The survey also highlights how manufacturers are now not
only facing weaker demand conditions due to the pandemic, but
are also seeing COVID-19 disrupt supply chains further, causing
shipping delays," Williamson adds. "These delays are limiting
production capabilities as well as driving producers' input
prices sharply higher, adding to the sector's woes."

On Tuesday, the Institute for Supply Management's (ISM) more
closely-watched PMI report is expected to come in at 56.6.
ISM and Markit PMI differ in the weight they give
subcomponents such as new orders, employment and inventories.
The chart below shows how widely the two indexes can differ
although in recent months they appear closer to agreeing:

A separate report from the Commerce Department showed
expenditures on construction projects increased by
0.9% in November, a hair slower than the 1% analysts expected.

Still, this is on the back of October's upwardly-revised
1.6% growth.
The gains were driven by a 2.7% jump in spending on
residential projects, as homebuilders struggle to keep pace
spiking demand for lower-density communities and work-from-home
office space amid pandemic restrictions.
The headline number was limited, however, by decreases in
nonresidential and public projects, which eased by 0.8% and
0.2%, respectively.
Strong residential activity has driven construction past
pre-pandemic levels, but non-residential outlays remain nearly
6% below their early 2020 pace," says Nancy Vanden Houten, lead
U.S. economist at Oxford Economics.

Market participants were unimpressed however and all three
major U.S. stock indexes reversed early gains in morning
trading.
(Stephen Culp)
*****

WALL STREET TAKES A NEW YEAR'S DIP TO KICK OFF 2021 (1025
EST/1525 GMT)
Wall Street's three major averages are having a bumpy start
to the trading year, starting higher before losing gains.
One thing on investors minds was Tuesday's twin U.S. Senate
runoff elections in Georgia, which will determine control of the
chamber and, effectively, the fate of President-elect Joe
Biden's agenda including rewriting the tax code, boosting
stimulus and infrastructure spending.
Encouraging progress in COVID-19 vaccines came with news of
surging cases and restrictions. Moderna is up almost 4%
after raising its 2021 vaccine output forecast.
But as Britain was first to began vaccinations with Oxford
University and AstraZeneca's COVID-19 shot on Monday, a
new surge of cases threatened to overwhelm its hospitals.
Scottish First Minister Nicola Sturgeon imposed the most
stringent lockdown since last spring.
In the United States the U.S. Centers for Disease Control
and Prevention (CDC) on Sunday reported 349,246 deaths from the
new coronavirus, a rise of 2,321 deaths from its previous count.
Vaccinations here have fallen far short of early
targets, as officials had hoped to have 20 million people
vaccinated by the end of the 2020.
Among S&P 500 major industry sectors only two were in
solidly positive territory with the biggest gains in the energy
sector and materials, both up almost 1%.
Here is your opening snapshot:



(Sinéad Carew)
*****


S&P 500: ANOTHER DASHBOARD LIGHT TURNS ON (0900 EST/1400
GMT)
The S&P 500 ended Friday at a fresh record high after
tacking on 16.3% in 2020. To get there, the benchmark index
advanced about 68% off its March 2020 closing low.
With this, in a sign of what may be an especially overheated
market, the percentage of S&P 500 stocks above their 200-day
moving average reached a more than 10-year high in early
December, when it hit 91.68%.
After dipping to about 88% on December 22, this measure
ended the year at about 91%. Although, only slightly below the
early December peak, it is nevertheless, weaker, despite the SPX
going to higher highs.
That said, it remains to be seen if this slight divergence
is enough to ultimately coincide with a SPX top of some form. Of
note, when the SPX peaked in February this measure had weakened
from a high of nearly 85% in January to about 76% when the SPX
topped on February 19th.
Meanwhile, another measure, based on the CBOE equity/put
call ratio, which can act as a contrarian measure of sentiment,
is suggesting the market is vulnerable to a reversal.




(Terence Gabriel)
*****


FOR MONDAY'S LIVE MARKETS' POSTS PRIOR TO 0900 EST/1400 GMT
- CLICK HERE:








(Terence Gabriel is a Reuters market analyst. The views
expressed are his own)

More News
22 Dec 2023 07:17

AstraZeneca gets FDA green light for nerve disease treatment

(Sharecast News) - The US Food and Drug Administration has approved the Wainua nerve disease treatment jointly developed by AstraZeneca and Ionis Pharmaceuticals.

Read more
19 Dec 2023 19:56

US adds 13 companies in China to Unverified List

WASHINGTON, Dec 19 (Reuters) - The United States has added 13 companies in China to a list of entities receiving U.S. exports that officials have been unable to inspect, according to a government notice posted on Tuesday.

Read more
15 Dec 2023 17:14

London stocks log weekly gains as cenbank fest ends

FTSE 100 down 1.0%, FTSE 250 off -0.3%

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
13 Dec 2023 17:07

UK's FTSE 100 rises as pound slips on GDP data; awaits Fed rate decision

UK economy shrinks by 0.3% in October

*

Read more
12 Dec 2023 16:00

London close: Stocks slip as investors digest US inflation

(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.

Read more
12 Dec 2023 12:07

London midday: FTSE still firmer ahead of US inflation print

(Sharecast News) - London's markets remained relatively stable by midday on Tuesday, with the top-flight index still in the green after fresh jobs data showed a slowdown in wage growth.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:53

LONDON MARKET OPEN: FTSE 100 opens higher ahead of US CPI

(Alliance News) - Stock prices in London opened higher on Tuesday, as investors digest the latest UK unemployment data, before turning their eyes to US inflation this afternoon.

Read more
12 Dec 2023 08:37

AstraZeneca acquires vaccine developer Icosavax for USD1.1 billion

(Alliance News) - AstraZeneca PLC confirmed on Tuesday that it will buy Icosavax Inc, boosting its vaccine portfolio with an "innovative" treatment for respiratory viruses.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:16

AstraZeneca to buy US vaccine maker Icosavax for up to $1.1bn

(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy Icosavax - a US-based clinical-stage biopharmaceutical company - for up to $1.1bn.

Read more
12 Dec 2023 02:00

UK companies pause China investment decisions as economy slows, survey shows

BEIJING, Dec 12 (Reuters) - A slowdown in both the Chinese and global economies is the biggest issue affecting British firms in the world's second-largest economy, beating geopolitical concerns and market access barriers, according to the British Chamber of Commerce in China.

Read more
11 Dec 2023 08:15

AstraZeneca says danicopan tests well as blood disorder treatment

(Alliance News) - AstraZeneca PLC on Monday reported "positive results" from a test of danicopan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, a rare and severe blood disorder.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.